Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma

Multikinase inhibitors (MKI) and mammalian target of rapamycin (mTOR) inhibitors prolong progression-free (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC) by reducing angiogenesis and tumor growth. In this regard, the MKI lenvatinib and the mTOR inhibitor ev...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Mol Sci
Autori principali: Bendtsen, Mathias Alrø Fichtner, Grimm, Daniela, Bauer, Johann, Wehland, Markus, Wise, Petra, Magnusson, Nils E., Infanger, Manfred, Krüger, Marcus
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2017
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5578126/
https://ncbi.nlm.nih.gov/pubmed/28796163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18081736
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi